Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles

By S. Dhar, F. Gu, Robert Langer, O. Farokhzad, S. Lippard. Proceedings of the National Academy of Sciences of the United States of America, 2008

960 citations recorded by the source corpus.

Subfields: Biomaterials, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/39e4a2ca1775c3b5670266df7336a68fc4a168ee

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Molecular Biology

Citations in the corpus

Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier (2011, background): “Various mechanisms of targeted delivery of drugs from diblock nanoparticles have also been reported [18,23,24].”
Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. (2016, methodology): “eliver a minimal dosage of cisplatin specifically to prostate caner cells with greater efficacy than free cisplatin (Dhar et al., 2008; arokhzad et al., 2006).”
Assessment of the Evolution of Cancer Treatment Therapies (2011, background): “[65] synthesized Pt(IV)-encapsulated prostate-specific membrane antigen targeted nanoparticles of poly(D,L-lactic-co-glycolic acid) (PLGA)-poly(ethylene glycol) (PEG)-functionalized controlled release polymers.”
Cancer active targeting by nanoparticles: a comprehensive review of literature (2014, background): “A similar strategy was reported by Dhar et al. (2008) to deliver cisplatin to prostate cancer cells by constructing Pt(IV)-encapsulated PSMA aptamer-targeted nanoparticles.”
Cisplatin: The first metal based anticancer drug. (2019, background): “[249,250] synthesized a novel Pt(IV) prodrug delivery system in which cis,cis,trans-[Pt(NH3)2Cl2(O2CCH2CH2CH2CH2CH2)2] was encapsulated within PLGA-b-PEG-COOH nanoparticles and theses nanoparticles were then functionalized with aptamers (Apt) that targeted to prostate-specific membrane antigen (see ”
Nanomedicine in cancer therapy (2023, background): “218 In a recent study, a PSMA-binding 2 ′ - ﬂ uoro-modi ﬁ ed RNA aptamer A9g was displayed on the surface of survivin siRNA-loaded extracellular vesicles (EVs) for targeted cancer therapy in a mouse model of human prostatic carcinoma.”
Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy (2016, background): “The nanoparticles are designed to release cisplatin specifically in the redox environment (39).”
Current approaches in SELEX: An update to aptamer selection technology. (2015, background): “Some of these AMNVs revealed increased in many times rate of cytotoxicity in comparison to drug by itself due to efficient drug delivery (Dhar et al., 2008, Kolishetti et al., 2010).”
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics (2012, positive): “An aptamer-conjugated nanoparticle has been created for the delivery of cisplatin to prostate cancer cells (Dhar et al., 2008).”
pH-sensitive nano-systems for drug delivery in cancer therapy. (2014, background): “To improve the therapeutic index of cisplatin and to minimize its adverse side effects, cisplatin analog Pt(IV) prodrugs have been synthesized (Dhar et al., 2008).”
Aptamers as therapeutics (2010, background): “Some efficacy was also demonstrated with the chemotherapeutic drug cisplatin delivered to tumour cells via aptamer functionalized PLGA-PEG nanoparticle conjugates 130, 131 .”